HGH deficiency in children<unk>  hormone deficiency is treated by replacing<unk>  hormone. Lonapegsomatropin was approved for medical use in the United States in August 2021. HGH deficiency in adults The Endocrine Society has recommended that adult patients diagnosed with<unk>  hormone deficiency (GHd) be administered an individualized GH treatment regimen. With respect to diagnosis, their guidelines state that "adults patients with structural hypothalamic/pituitary disease, surgery or irradiation in these areas, head trauma, or evidence of other pituitary hormone deficiencies be considered for evaluation for acquired GHd" and that "idiopathic GHd in adults is very rare, and stringent criteria are necessary to make this diagnosis. Because in the absence of suggestive clinical circumstances there is a significant false-positive error rate in the response to a single GH stimulation test, we suggest the use of two tests before making this diagnosis." GH replacement therapy can provide a number of measurable benefits to GH-deficient adults. These include improved bone density, increased muscle mass, decrease of adipose tissue, faster hair and nail<unk> , strengthened immune system, increased circulatory system, and improved blood lipid levels, but long term mortality benefit has not yet been demonstrated. A peer-reviewed article published in 2010 indicates that<unk>  hormone (GH) replacement unequivocally benefits<unk> , body composition, cardiovascular risk factors and quality of life. Less is known about the effects of GH on learning and memory." Other As of 2004, GH has been approved by the U.S. Food and Drug Administration for treatment of other conditions such as: * In adults, wasting (or cachexia) caused by AIDS. * Turner syndrome epitomizes the response of non-deficient shortness. At doses 20% higher than those used in GH deficiency,<unk>  accelerates. With several years of treatment the median gain in adult height is about on this dose. The gains appear to be dose-dependent. It has been used successfully in toddlers with Turner syndrome, as well as in older girls. * Short-stature homeobox gene deficiency * Chronic kidney failure results in many problems, including<unk>  failure. GH treatment for several years both before and after transplantation may prevent further deceleration of<unk>  and may narrow the height deficit, though even with treatment net adult height loss may be about * Prader–Willi syndrome, a generally non-hereditary genetic condition, is a case where GH is prescribed for benefits in addition to height. GH is one of the treatment options an experienced endocrinologist may use when treating a child with PWS. GH can help children with PWS in height, weight, body mass, strength, and agility. . Reports have indicated increase of<unk>  rate (especially in the first year of treatment) and a variety of other positive effects, including improved body composition (higher muscle mass, lower fat mass); improved weight management; increased energy and physical activity; improved strength, agility, and endurance; and improved respiratory function. The Prader-Willi Syndrome Association (USA) recommends that a sleep study be conducted before initiating GH treatment in a child with PWS. At this time there is no direct evidence of a causative link between<unk>  hormone and the respiratory problems seen in PWS (among both those receiving and those not receiving GH treatment), including sudden death. A follow-up sleep study after one year of GH treatment may also be indicated. GH (specifically Pfizer's version, Genotropin) is the only treatment that has received an FDA indication for children with PWS. The FDA indication only applies to children. * Children short because of intrauterine<unk>  retardation are small for gestational age at birth for a variety of reasons. If early catch-up<unk>  does not occur and their heights remain below the third percentile by 2 or 3 years of age, adult height is likely to be similarly low. High-dose GH treatment has been shown to accelerate<unk> , but data on long term benefits and risks are limited. *Idiopathic short stature (ISS) is one of the most controversial indications for GH as pediatric endocrinologists do not agree on its definition, diagnostic criteria, or limits. The term has been applied to children with severe unexplained shortness that will result in an adult height below the 3rd percentile. In the late 1990s, the pharmaceutical manufacturer Eli Lilly and Company sponsored trials of their brand of rHGH (Humatrope) in children with extreme ISS, those at least 2.25 standard deviations below mean (in the lowest 1.2 percent of the population). These boys and girls appeared to be headed toward heights of less than 63" (160 cm) and 59" (150 cm) respectively. They were treated for about 4 years and gained in adult height. Controversy has arisen as to whether all of these children were truly "short normal" children, since the average IGF1 was low. Approval of HGH for the treatment of this extreme degree of shortness led to an increase in the number of parents seeking its use to make otherwise normal children a little taller.is
Growth hormone therapy
Pyrotherapy
Ketogenic diet
Gestalt therapy
Masculinizing hormone therapy
Hypophysectomy
Transgender hormone therapy
Hormone replacement therapy